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Magnetic resonance imaging (MRI) is one of the most widely-used non-invasive clinical imaging tools,
producing detailed anatomical images whilst avoiding side effects such as trauma or X-ray radiation
exposure. In this article, a new approach to non-invasive monitoring of drug release from a delivery
vehicle via MRI was developed, using pH-responsive Eudragit L100 and S100 fibres encapsulating
superparamagnetic iron oxide nanoparticles (SPIONs) and carmofur (a drug used in the treatment of
colon cancer). Fibres were prepared by electrospinning, and found to be smooth and cylindrical with
diameters of 645  225 nm for L100 and 454  133 nm for S100. The fibres exhibited pH responsive
dissolution behaviour. Around the physiological pH range, clear pH-responsive proton relaxation
rate changes due to matrix swelling/dissolution can be observed: r2 values of L100 fibres increase
from 29.3  8.3 to 69.8  2.5 mM1 s1 over 3 h immersion in a pH 7.4 medium, and from 13.5 
2.0 mM1 s1 to 42.1  3.0 mM1 s1 at pH 6.5. The r2 values of S100 fibres grow from 30.4  4.4 to
64.7  1.0 mM1 s1 at pH 7.4, but at pH 6.5, where the S100 fibres are not soluble, r2 remains very low
(o 4 mM1 s1). These dramatic changes in relaxivity demonstrate that pH-responsive dissolution results
in SPION release. In vitro drug release studies showed the formulations gave rapid release of carmofur
at physiological pH values (pH 6.5 and 7.4), and acid stability studies revealed that they can protect the
SPIONs from digestion in acid environments, giving the fibres potential for oral administration.
Exploration of the relationship between relaxivity and carmofur release suggests a linear correlation
(R2 4 0.94) between the two. Mathematical equations were developed to predict carmofur release
in vitro, with very similar experimental and predicted release profiles obtained. Therefore, the
formulations developed herein have the potential to be used for non-invasive monitoring of drug
release in vivo, and could ultimately result in dramatic reductions to off-target side effects from
interventions such as chemotherapy.
Introduction
Among a wide variety of available clinical imaging techniques,
magnetic resonance imaging (MRI) stands out for its ability to
achieve high spatial and temporal resolution without the use
of ionizing radiation.1,2 In order to provide early and precise
diagnosis, contrast agents (CAs) are generally employed to
enhance resolution and contrast in MRI.3 Superparamagnetic
iron oxide nanoparticles (SPIONs) represent an important class
of MRI CA because of their size-dependent magnetic behaviour.4
By creating local magnetic field gradients, SPIONs can significantly
decrease proton transverse relaxation times (T2), boosting
signal contrast.5,6 Their relatively low cytotoxicity and ability
to be metabolized by normal biochemical pathways, alongside
their unique magnetic properties, also makes SPIONs useful
for a range of biological applications, including hyperthermia
and magnetic targeting.7–10 For example, SPIONs have been
explored for the targeted delivery of chemotherapeutics or for
local temperature-induced apoptosis.11 Recent studies into the
co-delivery of drugs and SPIONs showed excellent targeting
efficiency and MRI contrast coupled with minimal toxicity.12,13
However, few SPION-based systems have received regulatory
approval (e.g., GastroMARKs, Feridexs, Resovists and Ferahemes),
and of those that have been approved a number have subsequently
been withdrawn from the market.14,15
SPIONs are highly sensitive to external conditions: for
instance, they can be oxidised in an acidic environment, and
they have a tendency to aggregate.16 Hence, for biological
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applications, SPIONs are often coated or surface modified with
a biocompatible polymer, such as polyethylene glycol (PEG),
polylactic-co-glycolic acid (PLGA) or polyvinyl alcohol (PVA),
or natural materials such as dextran, heparin, gelatin or
chitosan.17,18 This approach provides protection from aggrega-
tion or degradation, and also offers the opportunity for multi-
functionality, such as the loading of a therapeutic active
ingredient or specific location targeting.19
Electrospinning is a straightforward technique which can
produce polymer-based nanoscale fibres via the application of
an electrical field to a polymer solution.20 It has been widely
explored to produce materials for a variety of fields, including
tissue engineering, biosensors, wound dressings, and drug
delivery.21–23 Only a few studies have probed the incorporation
of SPIONs into electrospun fibres for biological applications,
but there is clear promise: Huang et al. reported polystyrene
fibres with a high loading capacity of SPIONs, with the resultant
formulation effective in killing cancer cells via magnetic
hyperthermia.24 In other work, Wang et al. revealed that
drug-loaded dehydroxypropyl methyl cellulose phthalate and
cellulose acetate fibres encapsulating SPIONs demonstrated
superparamagnetism at room temperature, indicating the
feasibility of magnetic-field induced release.25 Exploitation of
the MRI activity of SPIONs for monitoring drug release from
electrospun fibres, on the other hand, has never been pre-
viously reported, despite its clinical utility and promise. The
environment surrounding SPIONs is crucial to their MRI signal
boosting capabilities, with diffusive water access to nearby
particle surfaces providing strong signal enhancement. SPIONs
encapsulated within electrospun fibres are therefore expected
to have significantly lower proton relaxation rate enhancement
compared to non-encapsulated particles. This difference in
signal could be exploited as a mechanism for monitoring the
dissolution of the fibres, and quantifying both SPION and
loaded active ingredient release.
Zhu et al. recently reported PLGA nanoparticles loaded with
the anti-cancer drug doxorubicin and SPIONs, and found these
to be potent for non-invasive MRI monitoring of drug delivery
both in vitro and in vivo after intratumoral injection.26 We
were interested here to develop a formulation which could be
given orally, rather than requiring an invasive injection for
delivery. To this end, SPIONs and carmofur (an adjuvant
chemotherapy for colon cancer, employed here as a model
anticancer drug) were loaded into pH-responsive fibres pre-
pared via electrospinning, to permit both pH-responsive drug
delivery and concurrent MRI-based monitoring of drug release
for application in the small intestine and colon. Two pH
responsive polymers (Eudragit L100 and S100, methacrylic
acid/methyl methacrylate copolymers which are only soluble
in water at pH 4 6.0 or 47.0, respectively) were used to form
the fibre filaments. These polymers can protect the SPIONs
from the acidic conditions encountered in the gastric fluid
following oral administration, and later dissolve to release
carmofur and expose the SPIONs (Scheme 1). The fibres
were fully characterised, and their drug release and proton
relaxivities investigated in detail.
Results and discussion
Physical and structural properties
SPIONs were initially synthesised using co-precipitation
and stabilised by polyvinylpyrrolidone (PVP) to prevent aggre-
gation. The as-prepared PVP-stabilised SPIONs (PVP-SPIONs)
possessed a mean size of 8.5  2.7 nm, as determined
by transmission electron microscopy (TEM; Fig. 1a and b).
The X-ray diffraction (XRD) patterns of the SPIONs and PVP-
stabilised SPIONs (Fig. 1c) match with the cubic cell of iron
oxide: the reflections at 30.2, 35.5, 43.7, 53.6, 57.1 and 62.91 can
be readily indexed to the (022), (311), (004), (333), (115), and
(044) planes of the cubic inverse spinel Fe3O4 (ICSD entry
77592). TGA of the PVP-SPIONs (Fig. S1, ESI†) revealed weight
loss of 3.4 wt% between 40 and 170 1C, due to the removal of
physisorbed water, and a weight loss of 6.2 wt% between 170
and 500 1C which can be attributed to the degradation of the
PVP stabiliser. SPIONs therefore comprise around 90 wt% of the
PVP-SPIONs mass.
PVP-SPIONs and carmofur were encapsulated within
pH-responsive Eudragit L100 or S100 nanofibres via electro-
spinning. Carmofur is a clinically approved antineoplastic agent
used to treat breast and colorectal cancer. It is an oral derivative
of fluorouracil and will be metabolised to 5-fluorodeoxyuridine
monophosphate in vivo, causing interference with RNA and DNA
synthesis.27,28 L100 and S100, anionic copolymers based on
methacrylic acid and methyl methacrylate, are only soluble
in water at pH 4 6.0 or 4 7.0, respectively. The resulting
L100/Carmofur/SPION and S100/Carmofur/SPION composite
fibres have uniform linear morphologies and smooth surfaces
(Fig. 1d–g), with mean fibre diameters of 645  225 and 454 
133 nm respectively (Fig. S2a, ESI† and Fig. 2b). The smaller
diameter of the S100/Carmofur/SPION composites is likely due
to the lower polymer concentration used for electrospinning
(10% and 12% w/v for Eudragit S100 and Eudragit L100, respec-
tively). This difference in solution concentration was necessary
due to the gel-like consistency of Eudragit S100 at high concen-
trations, which can clog the needle.
Scheme 1 The strategy underpinning nanoplatform design in this work.
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XRD patterns (Fig. 1c) of the fibres show the characteristic
reflections of cubic iron oxide, suggesting successful incorpora-
tion of PVP-SPIONs. The polymer raw materials are amorphous,
displaying only a broad background between 10–301 (see Fig. S3,
ESI†). The characteristic reflections of carmofur (Fig. S3, ESI†)
are not observed in the fibres’ XRD patterns, demonstrating that
it is likely present in the amorphous form in the electrospun
composite, owing to the very rapid drying which occurs during
electrospinning.29
The XRD findings are supported by differential scanning
calorimetry (DSC) analysis (Fig. 2a), where pure carmofur clearly
exists as a crystalline material with two sharp endothermic
melting peaks visible at ca. 114 and 115 1C, consistent with
the literature.30 The raw Eudragit polymers display a broad endo-
thermic peak between 60 and 120 1C (Fig. S4, ESI†), attributed to
the loss of adsorbed water. No events can be observed in the DSC
profile for PVP-SPIONs (Fig. 2a). S100/Carmofur/SPION and
L100/Carmofur/SPION fibres show broad shallow endotherms
between 40 to 80 1C, which can be ascribed to a loss of solvent
(ethanol or DMAc, employed during preparation, or adsorbed
water). The absence of the carmofur melting endotherm in the
DSC curves of the drug and PVP-SPION loaded fibres confirms
that it is present in the form of an amorphous solid dispersion.30
TGA curves indicate the presence of both the SPIONs
and carmofur within the fibres. S100/Carmofur/SPION and
L100/Carmofur/SPION fibres display multistage decomposition
steps (Fig. 2b). The small mass loss of about 3% before 110 1C
for both composite fibres can be attributed to solvent loss
(e.g., physisorbed water). Two subsequent decomposition
steps, between 100–160 1C and 220–300 1C, can be attributed
primarily to loss of the loaded carmofur (TGA data for pure
carmofur are shown in Fig. S5a, ESI†). A small mass loss
between 170 to 500 1C is caused by removal of PVP from the
loaded PVP-SPIONs (it is coincident with the mass loss in the
PVP-SPIONs TGA trace in Fig. S1a, ESI†). The final stage of
decomposition between 330 to 460 1C causes a weight loss of
around 54%, and mainly arises due to degradation of Eudragit
(see Fig. S5a for the raw Eudragit TGA data).
Fig. 1 (a and b) TEM images of PVP-SPIONs (8.5  2.7 nm); (c) XRD patterns of SPIONs, PVP-SPIONs and L100/Carmofur/SPION and S100/Carmofur/
SPION fibres, with ICSD entry 77592 representing cubic spinel iron oxide (black and dashed lines); SEM images of (d) and (e) L100/Carmofur/SPION
(645  225 nm) and (f) and (g) S100/Carmofur/SPION (454  133 nm) fibres.
Fig. 2 (a) DSC profiles of crystalline carmofur and S100/Carmofur/SPION and L100/Carmofur/SPION fibres; (b) TGA curves of the fibres.
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From the TGA of the fibres from three independent measure-
ments (Fig. 2b and Fig. S5b, c, ESI†), we can calculate that the iron
oxide content is around 20% w/w (17.3  0.34% w/w for L100/
Carmofur/SPION and 20.6  0.26% for S100/Carmofur/SPION;
mean  S.D., n = 3). This is slightly higher than the theoretical
loading (15.4% w/w for L100 and 17.9% w/w for S100 fibres). This
discrepancy arises because there is a small proportion of residual
decomposition products (expected to comprise carbon; around 3%)
which remain at 500 1C. The carmofur loadings of the L100/
Carmofur/SPION and S100/Carmofur/SPION fibres were measured
by UV-vis spectroscopy and calculated to be 7.5  0.4% and 8.0 
0.4% (mean S.D., n = 3), with encapsulation efficiencies of 96.1
4.9% and 100.1  5.4% respectively (mean  S.D., n = 3).
Fourier-transform infrared (FTIR) spectra of the L100/Carmo-
fur/SPION and S100/Carmofur/SPION fibres, as well as the raw
materials, are given in Fig. S6 (ESI†). Raw carmofur displays bands
at 1660–1720 cm1 and at 1495 cm1 arising from CQO stretching
vibrations. Eudragit L100 and S100 are both co-polymers of
methacrylic acid and methyl methacrylate, and share similar
spectra, with a characteristic stretch at 1727 or 1726 cm1 from
CQO vibrations of esterified carboxylic groups, as well as stretches
corresponding to ester groups between 1148 to 1251 cm1. The
presence of bands between 2900 and 2990 cm1 can be attributed
to the stretching vibrations of methylene groups. For the S100/
Carmofur/SPION and L100/Carmofur/SPION fibres, the character-
istic stretches of the polymer can be clearly identified, but with
shifts in their positions. The L100 and S100 CQO stretching
vibrations at 1726 or 1727 cm1 in the raw polymer move to
1721 or 1718 cm1 respectively in the fibres. These bands also
become broader, as they incorporate the stretches of carmofur
between 1666–1720 cm1. This suggests the successful incorpora-
tion of carmofur in these fibres.29
pH responsive properties
Non-encapsulated SPIONs are sensitive to highly acidic envi-
ronments such as those found in the stomach, resulting in
their oxidation, eventual dissolution, and loss of magnetic
properties. Their encapsulation in Eudragit-based fibres is
expected to overcome this issue, with the polymers providing
protection from acidic environments due to their lack of
solubility at low pH.31 In order to test their stability, 10 mg of
S100/Carmofur/SPION or L100/Carmofur/SPION fibres were
incubated in 25 mL of pH 1.5 aqueous HCl solution, similar
to the pH of gastric liquids.32 To compare their acid stability
with bare nanoparticles, 2 mg of PVP-SPIONs was subjected to
the same treatment. The release of Fe ions was measured using
an o-phenanthroline colorimetric assay after incubation at
37 1C for 2 h, which mimics the gastric transit time. The lmax
of the ferrous tris-o-phenanthroline product of dissolved iron
and o-phenanthroline is around 512 nm at neutral pH. Fig. 3a
shows that the [Fe] released from both types of fibres (green
and blue line) after 2 h was below that of a control FeCl3
aqueous solution ([Fe] 1 mg L1, black line), indicating less
than 2 wt% of the total SPION content was degraded in the
loaded fibres. This concentration is significantly lower than the
[Fe] released from bare PVP-SPIONs at equivalent concentra-
tions (between 1–10 mg L1, equating to up to 17 wt% degrada-
tion, purple line). These results show that the Eudragit coating
can protect the SPIONs from degradation in an acidic environ-
ment. Photographs (Fig. S7, ESI†) and SEM images (Fig. 3b–e)
of the loaded fibres following acid incubation demonstrate the
stability of the formulations: the morphology of the fibres appears
largely unaffected after exposure to the acidic conditions, and the
fibre size also remains similar, at 612  227 nm for the L100/
Carmofur/SPION fibres and 521  166 nm for S100/Carmofur/
SPION fibres (Fig. S2c and d, ESI†).
In order to mimic the conditions encountered during oral
delivery, where materials are likely to encounter a range of pH
environments (gastric pH is highly acidic (pH 1.0–2.5), while the
mean pH values in the proximal small intestine, colon and terminal
ileum are 6.6, 7.0 and 7.5),33 drug release experiments were
carried out at different pHs. Initially, S100/Carmofur/SPION
Fig. 3 The stability of PVP-SPIONs and the fibres after immersion at pH 1.5 for 2 h. (a) The results of colorimetric assays to determine [Fe] in solution
for PVP-SPIONs (purple), S100/Carmofur/SPION (blue) or L100/Carmofur/SPION (green) fibres with two control FeCl3 aqueous solutions (black and
red, 1 and 10 mg L1 respectively); SEM images of (b), (c) S100/Carmofur/SPION and (d), (e) L100/Carmofur/SPION fibres after immersion in pH 1.5
aqueous HCl for 2 h.
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and L100/Carmofur/SPION fibres were incubated at pH 1.5
(aqueous HCl solution) for 1 h, and then subsequently trans-
ferred to pH 6.5 or 7.4 PBS buffer. Carmofur release was
monitored by UV-vis measurement of the supernatant after
incubation (l = 262 nm, Fig. 4). Both sets of fibres demon-
strated release of around 35% of the drug content at pH 1.5
within the first hour. After introduction to PBS buffer, the
L100/Carmofur/SPION fibres exhibit similar release patterns
at both pH 6.5 and 7.4, with more than 90% release by 3 h and
100% release after 24 h. For the S100/Carmofur/SPION fibres,
carmofur release reaches 80% after 3 h after at pH 7.4, while it
takes longer (approximately 5 h) to reach this point at pH 6.5.
This is due to the different pH at which L100 and S100 become
water soluble. The polymer matrix in the S100 formulation
remains insoluble at pH 6.5, and the drug can only reach
the dissolution medium through diffusion or swelling of the
polymer and the permeation of water into the centre of the
fibres. At pH 7.4, S100 is water soluble and hence drug release
is mediated by polymer dissolution. In contrast, L100 is water
soluble at both pH 6.5 and 7.4 and therefore the release profiles
are essentially identical at both pH values.
Dynamic light scattering (DLS) size distribution profiles
further support the pH-sensitive dissolution properties of the
fibres. After the 24 h drug release study, the particle size of the
solid material in the dissolution medium was measured, and
the results are shown in Fig. S8 and Table S1 (ESI†). At both
pH 6.5 or 7.4, the L100/Carmofur/SPION fibres fully dissolve
after 24 h and yield a dispersion with a mean particle size of
591 32 nm and 380 11 nm (n = 3), suggesting the amphiphilic
copolymer might form micellar structures composed of a hydro-
phobic core and a shell with ionized carboxylate units.34
In contrast, the mean particle size of L100/Carmofur/SPION
fibres dispersed at pH 5.5 for 24 h was significantly higher
(3049 41 nm), suggesting the polymer fibres remain intact and
do not dissolve. S100/Carmofur/SPION composites displayed
analogous results in DLS, with a mean size of 458  31 nm at
pH 7.4, indicating dissolution, and 2959  176 nm at pH 6.5,
suggesting that no dissolution is taking place (n = 3).
To probe the mechanism of drug release, the Peppas model
(eqn (1)) was fitted to the drug release data.35 Mt/MN (Qt) repre-
sents the extent of drug release, t is the elapsed time, k is a rate




The first 60% of the release data fit well with the model, as
shown in Table 1 and Fig. S9 (ESI†). All the exponents at both
pH values are in the range 0.45 to 0.89, indicating drug release
occurs through a combination of matrix swelling and drug
diffusion.35
SPIONs are typically T2 contrast agents, providing negative
contrast by decreasing the transverse relaxation time of local
protons. To explore the efficiency of their contrast behaviour
when encapsulated within the composite fibres, the relaxivity
(r2) of L100/Carmofur/SPION and S100/Carmofur/SPION fibres
was initially measured in pH 7.4 PBS with 0.1% w/v xanthan




where r2 is relaxivity, R2,obs is the observed transverse relaxation
rate of the agent in aqueous suspension (R2 = 1/T2), R2,sol is the
relaxation rate of the blank solvent system (i.e., in the absence
of contrast agent) and [CA] is the mM concentration of the
contrast agent in suspension, as measured by inductively
coupled plasma – mass spectrometry (ICP-MS).
When fibres were immersed in the buffer, the initial
relaxivity r2 value (measured after 10 min suspension at
pH 7.4) was low (10.6  1.9 mM1 s1 for L100/Carmofur/
SPION, 12.0  3.6 mM1 s1 for S100/Carmofur/SPION). The r2
values increased with time as the fibres remained suspended in
buffer. This was due to the dynamic process of matrix dissolu-
tion/swelling, allowing water molecules access to the SPIONs,
boosting diffusive water access and hence enhancing their
relaxation rates and relaxivities. Therefore, instead of measuring
a single r2 value, the fibres’ r2 relaxivity was monitored as a
function of time during incubation in different pH PBS (6.5 or
7.4) with 0.1% w/v xanthan gum at 37 1C. The resultant r2 relaxivity
profiles can help to determine whether MRI signal could be
utilised as a mechanism of monitoring fibre dissolution/swelling,
and hence carmofur and SPION release.
Fig. 5a displays the transverse relaxivity (r2) profiles as a
function of immersion time at different pH. Due to the very low
Fig. 4 Plots showing the release of carmofur from the S100/Carmofur/
SPION and L100/Carmofur/SPION fibres, as measured by UV-vis spectro-
scopy (l = 262 nm). Data are given from three independent experiments as
mean  S.D.
Table 1 The results of fitting the Peppas model to carmofur release from
the fibres, constructed from the plots in Fig. S9 (ESI)
Fibres pH Peppas model R2
L100/Carmofur/SPION 7.4 Qt = 73.8t
0.75 0.99
6.5 Qt = 52.7t
0.53 0.98
S100/Carmofur/SPION 7.4 Qt = 61.6t
0.75 0.99
6.5 Qt = 35.6t
0.77 0.91
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initial relaxivity values, profiles were monitored from 10 min
immersion onwards. For L100/Carmofur/SPION fibres, the trans-
verse relaxivity increased rapidly and displayed pH-responsive
behaviour. At pH 7.4, r2 rose from 29.3  8.3 mM1 s1 after
10 min to 66.9  2.7 mM1 s1 over 40 min and subsequently
reached 69.8 2.5 mM1 s1 after 3 h, due to dissolution/swelling
and concomitant water access boosting relaxation rates as
previous described. At pH 6.5, the starting relaxivity value at
10 min (13.5  2.0 mM1 s1) was much lower than that
measured at pH 7.4, which is possibly because the L100
polymer is more hydrophilic at elevated pH owing to the
ionisation of carboxylic acid groups. This facilitates diffusive
water access to SPIONs and thus promotes transverse relaxation
in the suspension.34 The relaxivity increase is also slower at
pH 6.5, with r2 reaching 42.1  3.0 mM1 s1 after 3 h. After 3 h
of immersion, all the L100/Carmofur/SPION fibres had dis-
solved at both pH values, and the resultant solutions were clear
(Fig. S10, ESI†). However, the relaxivity value at pH 6.5 is
notably lower than at pH 7.4 after 3 h. This can be attributed
to the larger particle size of the dissolved L100/Carmofur/
SPION formulation at pH 6.5 (Fig. S8, ESI†). The amphiphilic
polymer might form micelle structures containing the SPIONs at
pH 6.5, with reduced diffusive water access meaning lessened
relaxivitiy enhancement, whereas at pH 7.4 the smaller particle
size results in a higher surface area to volume ratio and a greater
surface area for SPION–water interactions.
The S100/Carmofur/SPION fibres displayed a similar
relaxivity profile with respect to time at pH 7.4, with r2 values
of 30.4  4.4 mM1 s1 after 10 mins and 64.7  1.0 mM1 s1
after 3 h. The r2 values are overall slightly lower than those
observed for L100/Carmofur/SPION at the same pH, which
again can be attributed to the hydrodynamic size in the
suspension following dissolution. By plotting the r2 values
against the hydrodynamic diameter measured earlier (Fig. S8
and S11, ESI†), a clear inverse correlation is revealed. This is
consistent with the literature, where smaller particles with
increased surface areas allow improved water access to the
magnetic components, leading to boosted relaxivities.17 As pre-
viously noted, the S100-based fibres are insoluble at pH 6.5
(see Fig. S8 and S10, ESI†), and thus the r2 value remains
low throughout the experimental time as the SPIONs remain
encapsulated, preventing their effective magnetic interaction
with diffusive water protons.
According to the relaxivity profiles, it is clear that L100/
Carmofur/SPION composite fibres dissolve at pH 6.5 and 7.4
and S100/Carmofur/SPION fibres dissolve at pH 7.4 only,
resulting in the release and potential micellisation of SPIONs,
and hence increasing relaxivity due to increased water diffusive
access to magnetic centres. On the other hand, the S100/
Carmofur/SPION fibres do not demonstrate dissolution at
pH 6.5 (but show some evidence of swelling) and extended
immersion at this pH has little effect on the relaxivity. To prove
Fig. 5 (a) The change in transverse relaxation (r2) and (b) carmofur release from the S100/Carmofur/SPION and L100/Carmofur/SPION fibres as a
function of incubation time in PBS buffers with 0.1% w/v xanthan gum. (c) The relationship between relaxation behaviour (r2_t/r2_max) and cumulative
carmofur release.
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that SPIONs were released from the fibres as proposed, the Fe
concentration in solution was determined (Fig. S12, ESI†). The
solution [Fe] concentration vs. time plot mirrors the shape of
the r2 recovery profile, providing evidence that r2 is related to
the release of SPIONs from the fibres. Clear linear correlations
also can be observed between the concentration of Fe in the
supernatant and the relaxivity (Fig. S13, ESI†). Thus, the
recovery of r2 can be regarded as a kinetic process which is
proportional to the dissolution of the Eudragit fibres.
In order to directly compare drug release with the relaxivity
data, carmofur release from the fibres was quantified in PBS
with 0.1% xanthan gum, using UV-vis spectroscopy alongside
relaxivity changes (Fig. 5b). The presence of xanthan gum
causes the release milieu to have a gel-like consistency, which
makes it impossible to transfer between different pH values;
thus, experiments were performed only at pH 6.5 or 7.4, with no
initial acid stage. All the fibres displayed a rapid release of
carmofur in 3 hours, consistent with the in vitro drug release
tests performed without xanthan (Fig. 4). When the pH is above
that at which the Eudragit dissolves, the carmofur release
profile closely resembles the change in r2 with time. To explore
the relationship between carmofur release and relaxivity at these
pH values, plots of cumulative carmofur release vs. r2 were
constructed. These reveal a clear linear correlation between the
two parameters, with R2 ranging from 0.94 to 0.99 (Fig. S14 and
Table S2, ESI†). In contrast, for the S100/Carmofur/SPION fibres
at pH 6.5, a poor linear correlation (R2 = 0.83; Fig. S14, ESI†) was
observed. This arises because the fibres are insoluble at this pH,
so SPION release is minimal and the r2 value remains low
throughout the experimental period. This indicates that changes
in r2 signal directly correspond to carmofur release when the
pH is above that at which the Eudragit dissolves, meaning that
MRI could be exploited as a non-invasive means of monitoring
in situ drug release from such fibres in environments such as
the small intestine and colon. It should be noted that in the
gastrointestinal tract the presence of bile salts, or potentially
strong osmolarity in the colon, could affect the Eudragit dissolu-
tion process.36 However, it is clear from our data that there is a
strong correlation between the extent of carmofur release and
the r2 signal in pH conditions where the polymer is soluble,
regardless of the rate of dissolution. Thus, these additional
complexities in vivo are not expected to confound the findings
presented here. Our approach could hence provide a non-
invasive route to quantification of drug release at a site of
interest, and could prove particularly helpful in treatments using
highly toxic chemotherapy.
The MR signal intensity is related both to the relaxivity
properties of the CA and also to its local concentration.
However, the equations built considering r2_t (r2 at time t)
and cumulative carmofur release (Table S2, ESI†) only take
the relaxivity into consideration. In the clinic, the local CA
concentration might differ as a result of varied dosages, body
volumes or other pathological conditions. Hence, the r2 values
in each system were normalised by calculating r2_t/r2_max. The
r2_max is the maximum relaxivity value possible with the for-
mulation, which manifests in our experiments as the relaxivity
after 180 min, r2_180. Plots of drug release percentage vs. r2_t/r2_180
(Fig. 5c and Fig. S15, ESI†) reveal direct proportionality (except
with the S100/Carmofur/SPION fibres at pH 6.5), and the
normalised equations are given in Table 2. In the clinic, r2_t
could be regarded as the local MR signal intensity at a certain
time point, and r2_max as the theoretical maximum signal
intensity, a constant related to the specific formulation, dose
and individual. Compared to the equations built with only r2_t
and cumulative carmofur release (Table S2, ESI†), these nor-
malised equations also show good correlation coefficients but
can be more universally applied.
To further validate the predictive ability of the r2 data, the
equations correlating carmofur release (%) with relaxation
behaviour (Table 2) were applied to predict carmofur release
in a new series of experiments. Relaxation behaviour changes
were determined for L100/Carmofur/SPION and S100/Carmofur/
SPION fibres at different concentrations (n = 3) and used to
predict the extent of carmofur release. The latter was then
quantified by UV-vis spectroscopy and compared with r2 predic-
tions. The results are presented in Fig. 6. The predicted drug
release curves based on r2 are very similar to the data obtained by
UV-vis spectroscopy, indicating the potency of our theranostic
approach. Two fit factors F1 (the difference factor) and F2 (the
similarity factor) (eqn (3) and (4), respectively) were applied to
statistically compare the experimental dissolution profiles








F2 ¼ 50 log 100 1þ
P






Rt and Tt represents the percentage of active pharmaceutical
ingredient released from reference and test samples at time
point t, respectively, and n is the number of time points. F1 is
calculated from the relative error between the two release
curves.37 A value of F1 close to 0 suggests that two release
curves can be regarded as ‘equivalent’, while the FDA regards
an F1 of less than 15 to denote two release profiles being
similar.38 The F2 factor is a measurement of the mean differ-
ence between two release curves at each time point.34 Strong
similarity is indicated when F2 is close to 100.
39 A value of 50 is
obtained when the mean difference at each time point is 10%.
Table 2 The linear relationship between cumulative drug release and
relaxation behaviour (r2_t/r2_180), constructed from the plots in Fig. 5c
Formulation pH Fitting equation R2
Eudragit L100 6.5 Drug releaseð%Þ ¼ 97:3 r2 t
r2 180
þ 1:6 0.99
7.4 Drug releaseð%Þ ¼ 101:5 r2 t
r2 180
 8:9 0.94
Eudragit S100 7.4 Drug releaseð%Þ ¼ 105:8 r2 t
r2 180
þ 12:4 0.97
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Thus, two dissolution profiles are regarded to be ‘‘similar’’ by
the FDA if F2 is between 50 and 100.
39
Here we use the experimental release data obtained by
UV-vis spectroscopy as the reference (Rt), and the predicted data
as the test (Tt). The results are shown in Table 3. The F1 values of
L100/Carmofur/SPION fibres at pH 6.5 and S100 Carmofur/
SPION fibres at pH 7.4 lie in the range of ‘‘equivalent’’, while
for the L100 fibres at pH 7.4 most of the F1 values are also
consistent with equivalent release patterns. In terms of similarity
factor F2, the majority of the values are greater than 50. All these
results suggest the reliability of our predicted curves.
Novel pH-responsive fibres loaded with SPIONs and carmo-
fur were fabricated in this work to permit oral delivery of a
drug cargo to the intestine and colon. Predictive curves were
established to correlate MRI signal intensity and drug release,
thereby ultimately allowing non-invasive monitoring of local
drug release. Drug delivery for the treatment of colon cancer
remains a very significant challenge owing to the complicated
colon physiology and environmental barriers.40 The release and
absorption of chemotherapeutics can be markedly affected by
the changeable local environments and variable colonic
residence time, making it difficult ensure that effective
and safe doses are provided.40 Hence, the fact that our for-
mulations provide local release information offers great
potential benefits to control the delivered dose and provide
bespoke and personalised therapy in the clinic. This can ensure
that patients are given an appropriate dose to treat their disease
without experiencing dangerous or unpleasant side effects.
Unlike previous work,26,41 our fibres display pH-responsive
relaxation behaviour around the physiological pH, potentially
allowing them to be used to image abnormal local microenviron-
ments in intestinal and colon cancer.
Conclusions
Composite pH responsive nanofibres have been prepared
through electrospinning in this work. SPIONs (a negative
MRI contrast agent) and carmofur (a model drug) were incor-
porated into polymer fibres composed of pH-responsive and
biocompatible Eudragit polymers. Fibres with smooth cylindrical
morphologies were generated, with an amorphous dispersion of
carmofur. The encapsulation of SPIONs in the fibres led to
effective protection from digestion in the acid environment of
the stomach, and in vitro drug release studies reveal rapid release
of carmofur at the pH values typical of the small intestine
and colon. These results make our formulations promising as
oral-delivery systems for colonic cancer. The fibres also exhibit
pH responsive relaxation behaviour around the physiological pH
range, making them ideal candidates for the development of
ultra-sensitive reporters to detect abnormal microenvironments
in the small intestine and colon.
Fig. 6 Plots of experimental (black) and predicted (red) carmofur release curves: (a) L100/Carmofur/SPION fibres at pH 7.4, (b) L100/Carmofur/SPION
fibres at pH 6.5 and (c) S100/Carmofur/SPION fibres at pH 7.4. The predicted release data were calculated based on the relaxivity and the corresponding
experimental release data were obtained by UV-vis measurement. Experiments were performed in PBS at 37 1C with different fibre concentrations
(as labelled).
Table 3 F1 (difference factor) and F2 (similarity factor) values for the
predicted vs. experimental release plots
Sample Concentration (mg mL1) F1 F2
L100/Carmofur/SPION pH 7.4 2 8.71 47.6
1 16.1 59.6
0.5 8.58 48.3
L100/Carmofur/SPION pH 6.5 2 7.49 59.6
1 9.54 52.8
0.5 6.48 61.6
S100/Carmofur/SPION pH 7.4 2 14.1 58.1
1 7.69 41.2
0.5 10.9 56.2
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Further investigation of the fibres’ relaxivity behaviour
showed them to have pH responsive r2 profiles closely corre-
lated to the extent of drug release. On that basis, a novel
quantification method allowing drug release to be monitored
via proton relaxation changes was established and used to
predict with a high degree of accuracy the carmofur release
profiles in a new series of experiments. This offers the exciting
possibility to non-invasively monitor the extent of drug release
in situ. As most chemotherapeutic agents are cytotoxic and non-
specific, their safety remains a critical issue and hence our
formulations potentially open up a new route to dramatically
decrease off-target side effects in chemotherapy.
Experimental
Chemicals were purchased as follows: sodium hydroxide and
hydrous ethanol (Fisher Scientific Ltd); sodium chloride,
N,N-dimethylacetamide (DMAc), acetone, anhydrous ethanol,
polyvinylpyrrolidone (PVP; 40 kDa), hydroxylamine hydrochloride,
o-phenanthroline, xanthan gum, FeCl36H2O and FeCl24H2O
(Sigma-Aldrich); Eudragit L100 and S100 (Röhm GmbH); and,
Carmofur (ChemCruzt). Ultrapure water was collected from a
Millipore MilliQ system operated at 18.2 MO.
FeCl36H2O (6.5 g, 0.024 mol) and FeCl24H2O (2.48 g,
0.012 mol) were dissolved in 25 mL of deoxygenated ultrapure
water. This solution was added dropwise into 250 mL of an
aqueous NaOH solution (0.5 M) at 40 1C, and stirred for 1 h at
this temperature. The resultant SPIONs were washed by centrifu-
gation with DI water until the supernatant was pH neutral, and the
resultant black precipitate dried under vacuum. For PVP stabilisa-
tion, SPIONs (100 mL, 10 mg mL1 in water) were mixed with 2 mL
of an aqueous PVP 40k solution (25.6 g L1, 0.64 mM), and the
suspension was shaken (100 rpm) at room temperature. After 24 h,
the suspension was mixed with 500 mL of aqueous acetone (H2O/
acetone, 1 : 10 v/v) and centrifuged at 13 200 rpm for 20 min. The
supernatant was removed, and the resultant black precipitate
washed with ethanol and dried in an oven at 50 1C for 24 h.
A 12% (w/v) solution of Eudragit L100 and 10% (w/v)
solution of Eudragit S100 were prepared in a mixture of DMAc
and ethanol (2 : 8 v/v) and stirred vigorously for 24 h. Carmofur
(to give final concentrations of 12 or 10 mg mL1) and PVP-SPIONs
(at final concentrations of 24 or 20 mg mL1) were then added to
the Eudragit L100 or S100 solutions respectively, with sonication for
20 min. An HCP 35–35 000 power supply (FuG Elektronik GmbH)
was used to generate an electric field. A 5 mL plastic syringe fitted
with a narrow-bore stainless-steel needle (18 G, with outer and
inner diameter of 1.25 and 0.838 mm, respectively) was filled with
the required working solution. The spinneret was connected to the
positive electrode of the power supply via an alligator clip and a flat
plate aluminium collector attached to the grounded electrode. The
working solution was dispensed with the aid of a syringe pump
(KDS 100, Cole-Parmer) under ambient conditions (22  3 1C and
relative humidity 40  5%), with a flow rate of 1.0 mL/h. The
applied voltage and the distance from the spinneret to collector
were set to 16 kV and 15 cm, respectively.
A MiniFlex 600 diffractometer (Rigaku) supplied with Cu-Ka
radiation was used to collect XRD patterns (l = 0.15418 nm,
40 kV, 15 mA). Patterns were recorded over the 2y range from 3
to 701 (step = 0.011). The morphology of the fibres was analysed
with a field emission scanning electron microscope (FEI
Quanta 200F) connected to a secondary electron detector
(Everheart-Thornley Detector-ETD). Samples were coated with
a 20 nm gold sputter (using a Quorum Q150T coater) before
measurement. The size distribution of the fibres was deter-
mined from the SEM micrographs by measuring the fibres at
4100 points in the images, with the aid of the ImageJ software
(version 1.52s, National Institutes of Health).
TEM images were obtained on a JEOL JEM-1200 microscope
operated at 120 kV with a beam current of ca. 80 mA. A Gatan
Orius 11-megapixel camera was used to take images. TEM
samples were prepared by depositing a drop of PVP-stabilised
SPIONs in aqueous suspension on a formvar-coated 300-mesh
copper grid, and then drying the grids in the oven (45 1C).
Average particle size was measured with the ImageJ software
(version 1.52s, National Institutes of Health).
Thermogravimetric analysis was undertaken on a Discovery
instrument (TA Instruments, Waters LLC). Ca. 3 mg of each
sample was loaded into an aluminium pan and heated from 40
to 500 1C at 10 1C min1 under a nitrogen flow of 25 mL min1.
Data were recorded using the Trios software and analysed with
TA Universal Analysis. A Q2000 DSC (TA Instruments, Waters
LLC) was used for calorimetry. A small amount of sample
(approximately 3 mg) was loaded in a non-hermetically sealed
aluminium pan (T130425, TA instruments) and DSC experi-
ments carried out from 40 to 126 1C, with a temperature ramp
of 10 1C min1 and nitrogen purge of 25 mL min1. DSC data
were recorded with the TA Advantage software package and
analysed using TA Universal Analysis.
For ICP-MS, samples (containing ca. 0.06 mg SPIONs) were
digested using hot HNO3 digestion and then diluted to 10 mL
with DI water. The iron concentrations (mM) were quantified
on an Agilent 7500cx spectrometer.
An MQC+ benchtop NMR analyser (Oxford Instruments) was
used to measure transverse relaxation times (T2) of protons at
37 1C and 23 MHz. The Carr–Purcell–Meiboom–Gill (CPMG)
method was used to measure T2, with 4 scans per experiment.
The water relaxation rate enhancement per mmol of contrast
agent (relaxivity) is defined by eqn (2).
Stability studies were carried out by dispersing 10 mg of the
nanofibres or 2 mg of PVP-SPIONs in 25 mL of an aqueous HCl
solution (pH 1.5). Experiments were carried out in a shaking
incubator (100 rpm) at 37 1C for 2 h. The resulting solutions
were centrifuged for 15 min (13 200 rpm) to sediment any
undissolved fibres or particles. 5 mL samples of the super-
natants were removed and neutralised with a few drops of
aqueous 0.2 M NaOH. 0.9 mL of the neutralised sample was
added to 0.3 mL of a 10% (w/v) hydroxylamine hydrochloride
solution in water and 0.6 mL of an aqueous 0.2% (w/v)
o-phenanthroline solution. Finally, UV-vis spectra were recorded
on an Agilent Cary 100 spectrophotometer over the wavelength
range 370 to 800 nm.
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The loading capacity of carmofur (LC%) can be calculated as
the amount of entrapped drug divided by the total fibre weight.
Encapsulation efficiency (EE) is the percentage of the drug
present that is successfully entrapped into the fibres. To
calculate the loading and encapsulation efficiency of carmofur,
10 mg of the fibres (n = 5) was added into 10 mL of ethanol and
sonicated until the polymer was fully dissolved. A PVDF-type
syringe filter (0.22 mm) was used to filter the resultant solutions,
and the filtrates centrifuged for 10 min (13 200 rpm) to remove
the SPIONs. The supernatants were analysed with UV spectro-
scopy at 262 nm (Cary 100 instrument, Agilent), and the LC and
EE calculated based on a pre-determined calibration curve.
The carmofur release study was undertaken using a 50 mL
suspension of fibres (B0.5 mg mL1). Samples were incubated
in a pH 1.5 HCl solution for 1 h, and then transferred to pH 6.5
or 7.4 PBS. Experiments were undertaken in a shaking incuba-
tor (100 rpm) at 37 1C. 1 mL aliquots were withdrawn from the
dissolution medium at predetermined time points and filtered
through a PVDF-type syringe filter (0.22 mm). To maintain a
constant volume, 1 mL of fresh pre-heated buffer was added
to the dissolution vessel. The filtrates were centrifuged for
15 min (13 200 rpm) to remove any SPIONs, and then analysed
with an Agilent Cary 100 spectrophotometer. Carmofur quanti-
fications were performed at lmax of 262 nm. Dilutions were
undertaken when necessary to bring concentrations into the
linear range of the calibration curve. Experiments were per-
formed in triplicate and the results are reported as mean 
standard deviation (S.D.).
In a separate set of experiments, 5 mg of L100/Carmofur/
SPION fibres was incubated in 10 mL of pH 5.5 acetate buffer
under the same conditions as used for drug release (100 rpm,
37 1C). After 24 h, 2 mL aliquots were taken from each of the pH
7.4, 6.5 or 5.5 experiments for dynamic light scattering (DLS)
measurement. For the L100/Carmofur/SPION system at pH 5.5
and S100/Carmofur/SPION at pH 6.5, where the fibres were
aggregated in the form of mats, sonication was applied to
ensure a homogenous suspension was obtained before taking
aliquots and performing DLS measurements. To obtain the
particle size data, a ZetaSizer ZS instrument (Malvern) fitted
with a 4 mW He–Ne 633 nm laser module was used, and
scattered light measured at 1731 (back scattering). The attenua-
tor position was selected automatically by the instrument and
particle sizes are reported as the mean of 5 measurements.
Each sample was analysed three times.
To monitor changes in proton relaxivity, a dispersion of
approximately 10 mg of each fibre formulation in 8 mL of a
0.1% (w/v) aqueous xanthan gum solution was placed into a
10 mm-diameter NMR tube, which was held at 37 1C. The
transverse relaxation time (T2) was directly monitored over 3 h.
At predetermined time points, 0.3 mL of suspension was taken
from the NMR tube, diluted, and filtered through a PVDF-type
syringe filter (0.22 mm). To measure the free iron concentration,
suspensions were analysed by ICP-MS after hot nitric acid
digestion. To measure the carmofur concentration, centrifuga-
tion (13 200 rpm for 10 min) was conducted to remove the
SPIONs, and the supernatant analysed on an Agilent Cary
100 spectrophotometer. All experiments were performed in
triplicate and the results are reported as mean  S.D. In a set
of experiments to predict drug release, dispersions of fibre
samples at different concentration (0.5, 1.0 and 2 mg mL1) in
0.1% w/v xanthan gum buffer (n = 3) were placed into 10 mm
NMR tubes. The transverse relaxation time was monitored at
37 1C for 3 h. At selected time points, 0.3 mL aliquots were
taken from the NMR tube and the [Fe] and carmofur content in
each aliquot quantified as above.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
The authors gratefully thank Dr Andrew Weston for assistance
with electron microscopy experiments. The authors further acknow-
ledge financial support from the EPSRC (grants EP/N509577/1,
supporting AMK; and the EPSRC Centre for Doctoral Training
in the Advanced Characterisation of Materials (EP/L015277/1),
supporting CJRW).
References
1 E. Haacke and J. Reichenbach, Susceptibility weighted
imaging in MRI: basic concepts and clinical applications. John
Wiley & Sons, 2014.
2 G.-L. Davies, I. Kramberger and J. J. Davis, Chem. Commun.,
2013, 49, 9704–9721.
3 D. H. Carr, J. Brown, G. M. Bydder, R. E. Steiner,
H. J. Weinmann, U. Speck, A. S. Hall and I. R. Young, Am.
J. Roentgenol., 1984, 143, 215–224.
4 M. Mahmoudi, S. Sant, B. Wang, S. Laurent and T. Sen, Adv.
Drug Delivery Rev., 2011, 63, 24–46.
5 A. Neuwelt, N. Sidhu, C.-A. Hu, G. Mlady, S. C. Eberhardt
and L. O. Sillerud, Am. J. Roentgenol., 2015, 204, 302–W313.
6 R. Jin, B. Lin, D. Li and H. Ai, Curr. Opin. Pharmacol., 2014,
18, 18–27.
7 A. S. Perera, S. Zhang, S. Homer-Vanniasinkam, M.-O. Coppens
and M. Edirisinghe, ACS Appl. Mater. Interfaces, 2018, 10,
15524–15531.
8 T. Kang, F. Li, S. Baik, W. Shao, D. Ling and T. Hyeon,
Biomaterials, 2017, 136, 98–114.
9 S. Laurent, S. Dutz, U. O. Häfeli and M. Mahmoudi, Adv.
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